Zacks Investment Research on MSN
RXRX Q2 earnings miss estimates, revenues fall Y/Y, stock down
Recursion Pharmaceuticals RXRX reported a loss of 25 cents per share in the second quarter of 2026, wider than the Zacks ...
Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results